UC San Diego

UC San Diego Previously Published Works

Title

Jumbo phages are active against extensively drug-resistant eyedrop-associated Pseudomonas aeruginosa infections.

Permalink https://escholarship.org/uc/item/4vc4s6kw

Journal Antimicrobial Agents and Chemotherapy, 67(12)

Authors

Cobián Güemes, Ana Ghatbale, Pooja Blanc, Alisha <u>et al.</u>

Publication Date

2023-12-14

DOI

10.1128/aac.00654-23

Peer reviewed



8 | Bacteriophages | Full-Length Text

Jumbo phages are active against extensively drug-resistant eyedrop-associated *Pseudomonas aeruginosa* infections

Ana Georgina Cobián Güemes,¹ Pooja Ghatbale,¹ Alisha N. Blanc,¹ Chase J. Morgan,² Andrew Garcia,¹ Jesse Leonard,¹ Lina Huang,¹ Grace Kovalick,¹ Marissa Proost,¹ Megan Chiu,¹ Peiting Kuo,¹ Joseph Oh,¹ Smruthi Karthikeyan,^{3,4} Rob Knight,^{45,6,7} Joe Pogliano,²⁸ Robert T. Schooley,⁹ David T. Pride^{1,8,9}

AUTHOR AFFILIATIONS See affiliation list on p. 11.

ABSTRACT Antibiotic-resistant bacteria present an emerging challenge to human health. Their prevalence has been increasing across the globe due in part to the liberal use of antibiotics that has pressured them to develop resistance. Those bacteria that acquire mobile genetic elements are especially concerning because those plasmids may be shared readily with other microbes that can then also become antibiotic resistant. Serious infections have recently been related to the contamination of preservative-free eyedrops with extensively drug-resistant (XDR) isolates of Pseudomonas aeruginosa, already resulting in three deaths. These drug-resistant isolates cannot be managed with most conventional antibiotics. We sought to identify alternatives to conventional antibiotics for the lysis of these XDR isolates and identified multiple bacteriophages (viruses that attack bacteria) that killed them efficiently. We found both jumbo phages (>200 kb in genome size) and non-jumbo phages that were active against these isolates, the former killing more efficiently. Jumbo phages effectively killed the three separate XDR P. aeruginosa isolates both on solid and liquid medium. Given the ongoing nature of the XDR P. aeruginosa eyedrop outbreak, the identification of phages active against them provides physicians with several novel potential alternatives for treatment.

KEYWORDS jumbo phage, antibiotic resistance, *Pseudomonas aeruginosa*, eye drops, extensively drug resistant

A ntibiotic-resistant bacteria present a serious and growing challenge as their numbers continue to increase across the globe (1). Most notable among those organisms whose propensity for antibiotic resistance has posed a challenge are the ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella* sp., *Acinetobacter* sp., *Pseudomonas aeruginosa*, and *Enterobacter* sp.) pathogens, which are responsible for the majority of nosocomial infections worldwide (2). These particular microbes have the potential to be MDR (multi-drug resistant; resistant to at least one antimicrobial in three different classes of antimicrobials) or XDR (extensively drug resistant; resistant to almost all approved antimicrobials), and sometimes require the use of lesser-used antibiotics for treatment or antibiotic alternatives when they cause infections in humans (3). A recent outbreak of XDR *P. aeruginosa* contaminating eye drops in the U.S. is a perfect example of the threat that such microbes may pose to the population in the long term (4, 5). Thus far, there have been at least three fatalities secondary to these *P. aeruginosa* isolates, which are incredibly difficult to treat with conventional antibiotics (6).

Many bacteria are capable of acquiring new resistance genes through the process of conjugation where they may acquire mobile genetic elements such as plasmids (7). In the current outbreak, *P. aeruginosa* has acquired the Verona integron-encoded metallo-beta-lactamase (VIM beta-lactamase), which confers resistance to carbapenem antibiotics among others (8). This renders the organism very difficult to treat with

Editor Ryan K. Shields, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Address correspondence to David T. Pride, dpride@health.ucsd.edu.

Ana Georgina Cobián Güemes and Pooja Ghatbale contributed equally to this article. Author order was determined by alphabetical order.

The authors declare no conflict of interest.

See the funding table on p. 11.

Received 18 May 2023 Accepted 8 September 2023 Published 6 November 2023

Copyright © 2023 Cobián Güemes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. antibiotics, and because of the concern that it may be mobile, also raises significant concern for the spread of the carbapenemase to other bacteria.

Bacteriophages (viruses that attack bacteria) represent a rising therapeutic option for the treatment of antibiotic-resistant bacteria (9). Mechanisms that account for the reduced susceptibility of bacteria to antibiotics generally do not affect their susceptibilities to phages (10). Interest in the clinical use of phages for the treatment of drugresistant bacterial infections has been kindled by favorable outcomes reported in an increasing number of case reports and case series (11, 12). In view of the ongoing eyedrop-associated *P. aeruginosa* outbreak in the U.S., we examined a collection of anti-*Pseudomonas* phages against three XDR *P. aeruginosa* isolates that were obtained from patients affected by this outbreak to identify phages capable of killing them and to identify whether they may be capable of inhibiting the XDR isolates across different conditions.

RESULTS

Pseudomonas aeruginosa isolates

We obtained each of the three separate *P. aeruginosa* isolates responsible for the ongoing outbreak found in eyedrops (3) from the CDC/FDA AR Isolate Bank (https:// wwwn.cdc.gov/ARIsolateBank/; PS747, PS748, PS749, corresponding IDs in the AR bank are: 1268, 1269, and 1270). Antimicrobial susceptibility testing by microbroth dilution in the UC San Diego Center for Advanced Laboratory Medicine Clinical Microbiology Laboratory confirmed their XDR status (Table 1). The isolates were highly resistant to most beta-lactam antibiotics, including ceftolozane/tazobactam and ceftazidime/avibactam. Since the organisms possess a carbapenemase, treatment with meropenem and piperacillin/tazobactam would not be recommended despite intermediate MIC values in microbroth dilution assays. The only antibiotic to which the microbes demonstrated reproducible susceptibility was colistin (13).

We also sequenced each of the P. aeruginosa isolates obtained from the CDC in this study. Our results were largely consistent with the sequencing of the same reported by other groups (3). We assembled the genome sequences through a combination of Illumina short-read and Nanopore long-read sequencing. We confirmed that each of the genomes was generally roughly 7 Mbp in size, with nearly 66% G + C content (Table S1). Although we were able to sequence the genomes to near completion, we were not able to assemble the genomes below 25 separate 100 Kbp contigs. Many putative antibiotic-resistance genes were identified in the genome sequences, including those associated with resistance to beta-lactam, chloramphenicol, fosfomycin, macrolides, aminoglycosides, and fluoroquinolone antibiotics (Fig. 1, panel A). The VIM beta-lactamase sequence was identified in each of the organisms. Notably, a contig of 5 Kbp carries two beta-lactamases (VIM-2 and OXA-10), two aminoglycoside resistance genes, and a transposase (Fig. 1, panel B). A plasmid of 78 Kbp carries a transposase, two beta-lactamases (GES and CatB), and several other antibiotic-resistance genes (Fig. 1, panel C). Several complete anti-phage defense mechanisms were identified in the genomes (Fig. 1, panel D) including three types of restriction-modification systems, a dCTP deaminase involved in nucleotides depletion, a defense-associated reverse transcriptase, two recently discovered phage defense systems identified in phage T7, and eight other different defense systems.

Bacteriophages are active against XDR isolates

We tested a collection of phages to determine whether some were active against the XDR *P. aeruginosa* isolates and other recently identified clinical *P. aeruginosa* isolates (Table S2). We found 13 separate phages with activity against one or more of the *P. aeruginosa* isolates (Fig. 2, panel A). We first characterized the phage-host interactions using standard plaque assays on solid media. Two of the *P. aeruginosa* isolates were not lysed by any of the 13 phages in the collection. One or more phages exhibited lytic

TABLE 1 Antibiotic susceptibility of Pseudomonas aeruginosa epidemic isolates^a

Antibiotic	PS747	PS748	PS749	
Aztreonam	>16 (R)	>16 (R)	>16 (R)	
Ceftazidime	>16 (R)	>16 (R)	>16 (R)	
Cefepime	>16 (R)	>16 (R)	>16 (R)	
Meropenem	>8 (R)	8 (I)	8 (I)	
Piperacillin/Tazobactam	64 (R)	>64 (R)	32(I)	
Ceftolozane/Tazobactam	>8/4 (R)	>8/4 (R)	>8/4 (R)	
Ceftazidime/Avibactam	>16/4 (R)	>16/4 (R)	>16/4 (R)	
Ciprofloxacin	>2 (R)	>2 (R)	>2 (R)	
Levofloxacin	>4 (R)	>4 (R)	>4 (R)	
Gentamicin	>8 (R)	>8 (R)	>8 (R)	
Tobramycin	>8 (R)	>8 (R)	>8 (R)	
Amikacin	>32 (R)	>32 (R)	>32 (R)	
Colistin	≤2 (S)	≤2 (S)	≤2 (S)	

 ^{o}MIC values are shown in $\mu\text{g/mL}.$ Resistant (R), intermediate (I) or susceptible (S) MIC values are shown in parenthesis.

activity against each of the other 12 isolates. Nine of the thirteen phages exhibited lytic activity against one or more of the eyedrop-associated isolates, but only three phages produced clear plaques at the highest dilution tested (Fig. 2, panel A). The jumbo phages (tailed phage genomes > 200 kb) had significant lytic activity against the eyedrop


Gene product category	Numbe PS747 F	er of ge PS748 F		B PS748 Contig 81 5.278 bp
antibiotic inactivation enzyme				
peta-lactam resistance: OXA-10, OXA-50, GES-9, VIM-2, PDC-7	5	5	5	
chloramphenicol resistance: CatB family	2	2	2	
osfomycin resistance: FosA	1	1	1	
nacrolide resistance: EreA2	1	1	1	
aminoglycoside resistance gene, antibiotic inactivation enzyme				ANT(3")-la OXA-10 Transposase IS116 AAC(6')-lb VIM-2
AAC(6')-lb4, AAC(6')-lb9, APH(3'')-lb, APH(3')-lib, APH(6)-ld, AadA	5	7	7	
aminoglycoside resistance gene, antibiotic target modifying				
enzyme				
RmtF	2	2	0	C PS748 Contig 34
antibiotic resistant gene variant or mutant, fluoroquinolone		-	Ű	78,186 bp
resistance				78,186 bp
ParE, ParC, GyrA	3	3	3	
efflux pump conferring antibiotic resistance	Ŭ	Ŭ	Ŭ	
TetG	1	1	1	
QacE	1	1	1	GES AAC(6')-Ib Hypothetical CatB Hypoth
VexM	1	1	1	GES AAC(6')-Ib Hypothetical CatB Hypoth
MexHI-OpmD system	5	4	3	16S rRNA IS91, phage Puromycin
MexPQ-OpmE system	3	3	3	methyltransferase transposase N-acetyltransferase
	3	3	3	incuryinansiciase samptimes in accylinansiciase
MexCD-OprJ system				
MexAB-OprM system	3	3	3	D
MexAB-OprM system MexEF-OprN system	3	3 3	3 3	D Complete sys
MexAB-OprM system MexEF-OprN system MexVW-OprM system	3 3 2	3 3 3	3 3 3	
MexAB-OprM system MexEF-OprN system MexVW-OprM system MexXYAxyXY	3 3 2 2	3 3 3 4	3 3 3 2	Defense system Complete sys
MexAB-OprM system MexEF-OprN system MexVV-OprM system MexXYAxyXY MexJK-OprM/OpmH system	3 3 2 2 2	3 3 4 3	3 3 3 2 3	Defense system Complete sys PS747 PS748 Restriction modification
MexAB-OprM_system MexEF-OprN_system MexWV-OprM system MexXVYAxyXY MexJK-OprM/OpmH_system TriABC-OpmH system	3 3 2 2 2 4	3 3 4 3 3	3 3 2 3 4	Defense system Complete sys PS747 Restriction modification 4 Type I 4
MexAB-OprM system MexEF-OprN system MexWV-OprM system MexXY/AxyXY MexJK-OprM/OpmH system TriABC-OpmH system Em/AB-OMF efflux system	3 3 2 2 2 4 3	3 3 4 3 3 3 3 3	3 3 2 3 4 3	Defense system Complete sys PS747 Restriction modification 7 Type I 4 4 Type IIG 1 1
MexAB-OprM system MexEF-OprN system MexVVW-OprM system MexXYAxyXY MexJK-OprM/OpmH system TriAB-OCMF efflux system MdtABC efflux system	3 3 2 2 2 4 3 5	3 3 3 4 3 3 5	3 3 2 3 4 3 6	Defense system Complete sys PS747 PS748 Restriction modification Type I 4 4 Type I/V 1 1
MexAB-OprM system MexEF-OprN system MexTVV-OprM system MexXVV-OprM/OpmH system TinABC-OpmH system EmrAB-OMF efflux system dtABC efflux system MdtABC efflux system	3 3 2 2 2 4 3 5 2	3 3 3 4 3 3 3 5 2	333234362	Defense system Complete sys PS747 Restriction modification 4 Type I 4 4 Type IIG 1 1 Type IV 1 1
MexAB-OprM system MexXE-OprN system MexXV-OprM system MexXY/AxyXY MexJK-OprM/OpmH system TirABC-OpmH system EmrAB-OMF efflux system MdtABC efflux system Macrolide export proteins MacA, MacB TioR family	3 3 2 2 2 4 3 5	3 3 3 4 3 3 5	3 3 2 3 4 3 6	Defense system Complete sys PS747 PS748 Type I Type IIG 4 4 Type IIG 1 1 Type IV 1 1 Phage defense PD-T7-1 1
MexAB-OprM system MexXP-OprM system MexVVM-OprM system MexXVAxyXY MexXI-CoprM/OprH system TriABC-OpmH system TriABC-OF efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux	3 3 2 2 2 4 3 5 2 2	3 3 4 3 3 3 5 2 2	3 3 3 2 3 4 3 6 2	Defense system Complete sys PS747 Score Restriction modification 4 4 Type IIG 1 1 Type IV 1 1 Phage defense PD-T7-1 1 1
MexAB-OprM system MexZF-OprN system MexXV-OprM system MexXVX-OprM/OpmH system EmrAB-OMF efflux system EmrAB-OMF efflux system MdtABC efflux system Septem odulating antibiotic efflux CrR family, PhoQ, PhoP, NtxB, MerR, MexZ, MexS	3 3 2 2 2 4 3 5 2	3 3 3 4 3 3 3 5 2	3 3 3 2 3 4 3 6 2	Defense system Complete sys PS747 Restriction modification 4 Type II 4 4 Type IV 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Nucleotide depletion 1 1
MexAB-OprM system MexZE-OprN system MexXV-OprM system MexXY/AxyXY MexJK-OprM/OpmH system TinABC-OpmH system EmrAB-OMF efflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB TioR family gene modulating antibiotic efflux AcrR family, PhoP, NfxB, MerR, MexZ, MexS protein modulating permeability to antibiotic	3 3 2 2 2 4 3 5 2 2	3 3 4 3 3 3 5 2 2	3 3 2 3 4 3 6 2 2	Defense system Complete sys PS747 Restriction modification 4 Type IIG 1 1 Type IV 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Outleotide depletion 1 1
MexAB-OprM system MexZF-OprN system MexXV-OprM system MexXVX-OprM/OpmH system EmrAB-OMF efflux system EmrAB-OMF efflux system MdtABC efflux system Septem odulating antibiotic efflux CrR family, PhoQ, PhoP, NtxB, MerR, MexZ, MexS	3 3 2 2 2 4 3 5 2 2	3 3 4 3 3 3 5 2 2	3 3 2 3 4 3 6 2 2 10 10	Defense system Complete sys PS747 Complete system Restriction modification 4 4 Type I 1 1 Type I/G 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Other Completion 1 1 Other Completion 1 1 Defense associated reverse transcriptase 1 1
MexAB-OprM system MexZB-OprM system MexZF-OprN system MexXY/AxyXY MexXK-OprM/OpmH system EmrAB-OMF efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NKB, MerR, MexR, MexZ, MexS protein modulating permeability porin OprD family Duter membrane low permeability porin OprD family	3 2 2 2 4 3 5 2 2 2	3 3 4 3 3 5 2 2 2	3 3 2 3 4 3 6 2 2 2	Defense system Complete sys PS747 Restriction modification 4 Type I 4 4 Type I/G 1 1 Type I/C 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 OCTPdeaminase 1 1 Defense associated reverse transcriptase 1 1 DRT 2 1 1 1
MexAB-OprM system MexXB-OprM system MexVV-OprM system MexVV-OprM system MexXYAxyXY MexXI-CoprM/OprM system TriABC-OprM Felflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NKB, MerR, MexR, MexZ, MexS protein modulating permeability to antibiotic Duter membrane low permeability porin OprD family	3 3 2 2 2 4 3 5 2 2 2 10	3 3 4 3 3 5 2 2 2 10	3 3 2 3 4 3 6 2 2 10 10	Defense system Complete sys PS747 Complete system Type I 4 4 Type IIG 1 1 Type IV 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 OUCleotide depletion 1 1 Defense associated reverse transcriptase 1 1 DRT 2 1 1 tRNAse 1 1
MexAB-OprM system MexZB-OprM system MexZF-OprN system MexXY/AxyXY MexXK-OprM/OpmH system EmrAB-OMF efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NKB, MerR, MexR, MexZ, MexS protein modulating permeability porin OprD family Duter membrane low permeability porin OprD family	3 3 2 2 2 4 3 5 2 2 2 10 10	3 3 4 3 3 5 2 2 2 10 10	3 3 2 3 4 3 6 2 2 10 117 3	Defense system Complete sys PS747 PS748 Restriction modification 4 4 Type II 1 1 Type IIG 1 1 Type IV 1 1 PD-T7-1 1 1 PD-T7-4 1 1 OTPdeaminase 1 1 Defense associated reverse transcriptase 1 1 RIoC 1 1 1
MexAB-OprM system MexXB-OprM system MexXF-OprN system MexXY/AxyXY MexXK-OprM/OpmH system TinABC-OpmH system EmrAB-OMF efflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoP, NfxB, MerR, MexR, MexZ, MexS protein modulating permeability to antibiotic Duter membrane low permeability porin OprB family Sonspecific porin and structural outer membrane protein OprF	3 3 2 2 2 4 3 5 2 2 2 10 10	3 3 4 3 3 5 2 2 2 10 10	3 3 2 3 4 3 6 2 2 10 117 3	Defense system Complete sys PS747 Restriction modification 4 Type I 4 4 Type I/G 1 1 Type I/G 1 1 Type I/C 1 1 PD-T7-1 1 1 PD-T7-4 1 1 DEfense associated depletion 1 1 OEfense associated reverse transcriptase 1 1 DRT 2 tRNAse 1 1 RloC 1 1 1 Other defense systems 1 1 1
MexAB-OprM system MexZF-OprN system MexXF-OprN system MexXY-AxyXY MexXK-OprM/OprH system TriABC-OpmH system TriABC-OpmH system TriABC-MF efflux system MdtABC efflux system Macrolide export proteins MacA, MacB ToR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NKB, MerR, MexZ, MexZ protein modulating permeability to antibiotic Duter membrane low permeability porin OprD family Outer membrane low permeability porin OprD family Duter membrane low permeability porin OprB family Nonspecific porin and structural outer membrane protein OprF protein or gene altering cell wall charge conferring antibiotic	3 3 2 2 2 4 3 5 2 2 2 10 10 18 5	3 3 4 3 3 5 2 2 2 10 10	3 3 2 3 4 3 6 2 2 10 117 3	Defense system Complete sys pS747 PS748 Type I 4 4 Type IIG 1 1 Type IV 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Other defense 1 1 Defense associated reverse transcriptase 1 1 DRT 2 1 1 1 IROC 1 1 1 1 Hachiman 2 2 2
MexAB-OprM system MexZB-OprM system MexZF-OprN system MexXV-OprM/System MexXY/AxyXY MexJK-OprM/OpmH system EmrAB-OMF efflux system MotABC efflux sy	3 3 2 2 4 3 5 2 2 2 10 10 18 5 1	3 3 4 3 3 5 2 2 2 10 18 6 1	3 3 2 3 4 3 6 2 2 10 17 3 1	Defense system Complete sys PS747 Restriction modification 4 Type I 4 4 Type I/G 1 1 Type I/G 1 1 Type I/C 1 1 PD-T7-1 1 1 PD-T7-4 1 1 DEfense associated depletion 1 1 OEfense associated reverse transcriptase 1 1 DRT 2 tRNAse 1 1 RloC 1 1 1 Other defense systems 1 1 1
MexAB-OprM system MexEF-OprN system MexEF-OprN system MexXVY-OprM system MexXYVAxyXY MexJK-OprM/OpmH system EmrAB-OMF efflux system EmrAB-OMF efflux system Morrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NfxB, MerR, MexR, MexZ, MexS protein modulating permeability to antibiotic Duter membrane low permeability porin OprD family Duter membrane low permeability porin OprD family Sonspecific porin and structural outer membrane protein OprF protein or gene altering cell wall charge conferring antibiotic resistance SdpD, PgsA, PmrA, PmrB antibiotic target replacement protein	3 3 2 2 4 3 5 2 2 2 10 10 18 5 1	3 3 4 3 3 5 2 2 2 10 18 6 1	3 3 2 3 4 3 6 2 2 10 17 3 1	Defense system Complete sys pS747 PS748 Type I 4 4 Type IIG 1 1 Type IV 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Other defense 1 1 Defense associated reverse transcriptase 1 1 DRT 2 1 1 1 IROC 1 1 1 1 Hachiman 2 2 2
MexAB-OprM system MexZB-OprM system MexZF-OprN system MexXY-AvXY MexXK-OprM/OpmH system EmrAB-OMF efflux system MdtABC efflux	3 3 2 2 4 3 5 2 2 2 10 18 5 1	3 3 4 3 3 5 2 2 2 10 10 18 6 1	3 3 2 3 4 3 6 2 2 2 10 10 17 3 1	Defense system Complete sys PS747 Restriction modification 1 Type I 4 4 Type I/G 1 1 Type I/G 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Defense associated reverse transcriptase 1 1 DT2 1 1 DRT 2 1 1 IROC 1 1 Hachiman Cother defense systems 1 Kiwa 2 2
MexAB-OprM system MexZB-OprM system MexZF-OprN system MexXY-AvxXY MexXK-OprM/OprM system TriABC-OprM system EmrAB-OMF efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux ActrR family, PhoQ, PhoP, NKB, MerR, MexZ, MexS protein modulating permeability to antibiotic Duter membrane low permeability porin OprB family Outer membrane low permeability porin OprB family Nonspecific porin and structural outer membrane protein OprF protein or gene altering cell wall charge conferring antibiotic Tesistance SdpD, PgsA, PmrA, PmrB antibiotic target replacement protein HtdX, FabG, FabV, Sul1, DfrA5	3 3 2 2 4 3 5 2 2 2 10 18 5 1	3 3 4 3 3 5 2 2 2 10 10 18 6 1	3 3 2 3 4 3 6 2 2 2 10 10 17 3 1	Defense system Complete sys PS747 PS748 Type I 4 4 Type IIG 1 1 Type IV 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Other defense 1 1 PD-T7-4 1 1 DEfense associated reverse transcriptase 1 1 DRT 2 tRNAse 1 1 RloC 1 1 1 Machiman 2 2 2 Kiwa 1 1 1 Lamassu 1 1 1
MexAB-OprM system MexEF-OprN system MexEF-OprN system MexXV-OprM system MexXYV-ApxXY MexJK-OprM/OpmH system FinABC-OpmH system FinABC-OpmH system Sericle export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NfxB, MerR, MexR, MexZ, MexS protein modulating permeability to antibiotic Duter membrane low permeability porin OprD family Duter membrane low permeability porin OprD family Mex Duter membrane protein OprD family Mex Duter mem	3 3 2 2 2 4 3 5 2 2 2 10 18 5 1 1 5 5 6	3 3 4 3 5 2 2 10 18 6 1 5 5	3 3 2 3 4 3 6 2 2 10 17 3 1 6 6	Defense system Complete sys pS747 PS748 Type I 4 4 Type IIG 1 1 Type IV 1 1 Phage defense 1 1 PD-T7-1 1 1 PD-T7-4 1 1 CTPdeaminase 1 1 DET 2 1 1 DRT 2 1 1 CtPdeaminase 1 1 DRT 2 1 1 Mokosh 1 1 Massure 1 1 DRT 2 2 2 Kiwa 1 1 Lamassu 1 1
MexAB-OprM system MexZB-OprM system MexZF-OprN system MexXY-AvXY MexXK-OprM/OpmH system Fin7ABC-OpmH system EmrAB-OMF efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system MdtABC efflux system Macrolide export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family gene modulating antibiotic efflux AcrR family gene modulating antibiotic efflux AcrR family gene modulating permeability poin OprD family Vorspecific porin and structural outer membrane protein OprF protein or gene altering cell wall charge conferring antibiotic resistance SdpD, PgsA, PmA, PmrB antibiotic target replacement protein HtdX, FabG, FabV, Sul1, DfrA5 regulator modulating expression of antibiotic resistance genes DxyR	3 3 2 2 2 4 3 5 2 2 10 18 5 1 5 5 6 6	3 3 4 3 3 5 2 2 10 18 6 1 5 5 5	3 3 2 3 4 3 6 2 2 10 17 3 1 6 6 1	Defense system Complete system PS747 Complete system Type I 4 4 Type IIG 1 1 Type IV 1 1 PD-T7-1 1 1 PD-T7-4 1 1 Otfense associated reverse transcriptase 1 1 DRT 2 1 1 1 CTPdeaminase 1 1 1 Otfense associated reverse transcriptase 1 1 1 RIoC 1 1 1 1 Ktwa 1 1 1 1 Machiman 2 2 2 1 1 Shango 1 1 1 1 1 1
MexAB-OprM system MexEF-OprN system MexEF-OprN system MexXV-OprM system MexXYV-ApxXY MexJK-OprM/OpmH system FinABC-OpmH system FinABC-OpmH system Sericle export proteins MacA, MacB FloR family gene modulating antibiotic efflux AcrR family, PhoQ, PhoP, NfxB, MerR, MexR, MexZ, MexS protein modulating permeability to antibiotic Duter membrane low permeability porin OprD family Duter membrane low permeability porin OprD family Mex Duter membrane protein OprD family Mex Duter mem	3 3 2 2 2 4 3 5 2 2 2 10 18 5 1 1 5 5 6	3 3 4 3 5 2 2 10 18 6 1 5 5	3 3 2 3 4 3 6 2 2 10 17 3 1 6 6	Defense system Complete system PS747 PS748 Type I 4 4 Type IIG 1 1 Type IV 1 1 PD-T7-1 1 1 PD-T7-4 1 1 DEFense associated reverse transcriptase 1 1 DRT 2 1 1 1 DRT 2 1 1 1 KINASe 1 1 1 Kiwa 2 2 2 Kiwa 1 1 1 Shango 1 1 1


FIG 1 Antibiotic-resistance genes and phage defense mechanisms in eyedrop-associated *Pseudomonas aeruginosa* genomes. (A) Antibiotic-resistance genes. Genome annotations were performed in the BV-BCR server using the CARD database. (B) Selected insertion sequence (IS) element of PS748. (C) Selected plasmid fragment in PS748. (D) Identified complete phage defense systems. Identification was performed using DefenseFinder.

isolates. These jumbo phages included the previously described PhiKZ (14) and PhiPA3 (15), but also two additional phages, ANB1 and PhiPizzaParty, which were found in this study.

Genome characterizations and imaging of phages

We characterized the genome and structures of the jumbo phages in this collection, which exhibited lytic activity against the outbreak-associated XDR *P. aeruginosa* isolates. Phages PhiPizzaParty and ANB1 were similar in size and gene content to PhiKZ (Fig.





3). They had many similarities and some differences along their genome structures, indicating that they were likely derived from similar ancestral phages (Fig. 3). We did not identify any gene content to suggest that they may be involved in lysogenic infections. The closest relative to PhiPizzaParty and ANB1 was phage SL2 (16), these phages have an identity greater than 97% between each other. They are substantially different from phage PA7 (NC_042060.1) and PhiPA3 (Fig. S1). Phage PhiPA3 performs generalized transduction (15); therefore, it was excluded from further analysis. Phages that perform generalized transduction are believed to be unsuitable for therapeutic applications since they could spread genes between bacteria. We found that phage PhiPizzaParty was 98.4% similar to PhiKZ, with most of the differences arising in the gene structures of endonucleases, structural head protein, tail fibers, and other proteins without annotation. Phage ANB1 was 98% similar to PhiKZ than PhiPizzaParty (Fig. S1). The genomes for non-jumbo phages were also sequenced (Fig. S2).

We previously demonstrated that many *Pseudomonas* jumbo phages including PhiKZ replicate by enclosing their genome within a proteinaceous shell, forming a structure (phage nucleus) that segregates phage DNA from the host cell cytoplasm (17–19). Nucleus-forming phages are particularly well-suited for phage therapy because they are broadly immune to many bacterial phage defense systems (20, 21). The gene that encodes the nuclear shell protein, Chimallin (22, 23), in PhiKZ and other nucleus-forming phages was present in both PhiPizzaParty and ANB1. To determine whether these phages also formed a phage nucleus, we performed fluorescence microscopy on phage-infected cells (Fig. 4, panels N through P). Imaging of DAPI-stained infected cells showed that, similar to PhiKZ, PhiPizzaParty and ANB1 degrade the host chromosome and center its genome in the cell in a manner that is consistent with nucleus-forming




FIG 3 Comparative genomics of jumbo phages. Jumbo phages tested against XDR *Pseudomonas aeruginosa* eyedrop isolates (A, B, C and F) and its closest relatives (D and E). Jumbo phages PhiPizzaParty (B) and ANB1 (C) were discovered in this study. Comparative genomics were performed in the VIP tree server.

phage. Together, this supports the conclusion that PhiPizzaParty and ANB1 are nucleus-forming phages.

TEM analysis

We imaged each of the phages in this study using transmission electron microscopy (TEM) to further determine their structures. The images of each of the phages demonstrate that most have an icosahedral head structure with relatively long,




FIG 4 TEM of phages used in this study. (A–D) Jumbo phages. (E–M) Non-jumbo phages. (N–P) Fluorescence microscopic images of *Pseudomonas aeruginosa* infected with phage PhiKZ, Phi Pizza Party, and ANB1, respectively. The cell membrane is stained with FM4-64 (red), and the DNA is stained with DAPI (cyan). The phage nucleus-like structure can be seen centered in the cell.

noncontractile tail structures as are often observed in the family *Siphoviridae* (Fig. 4, panels A through M) (24). Phage Teru, which was also active against many of the *P. aeruginosa* isolates, was the most notable exception with more of a tail stub similar to that observed in the family *Podoviridae* (Fig. 4, panel E).

Efficiency of plating analysis

To further characterize the activity of the phages against the XDR *P. aeruginosa* isolates, we performed an efficiency of plating (EOP) analysis in all phages that infect the eyedrop-associated isolates (Fig. 2, panel B; Table S4). Most of the non-jumbo phages produced low EOP values, with phages Good Vibes, Clover, Sealy, and Kat producing EOP values lower than 10^{-3} (Fig. 2, panel B; Table S4). Phage Teru was the only non-jumbo phage to produce EOP values similar to those of the jumbo phages; this was because Teru's titer in the reference strain PAO1 was lower than the rest of the phages. The jumbo phages produced EOP values greater than 10^{-3} in most cases, with PhiKZ and ANB1 producing values $\geq 10^{-3}$ for each of the XDR isolates. Phage PhiPizzaParty produced EOP values $\geq 10^{-3}$ for isolates PS748 and PS749, but not for PS747.

Liquid media suppression

We sought to determine whether our jumbo phages also might be active in a liquid medium in addition to the solid medium against the XDR *P. aeruginosa* isolates. There was substantial inhibition of each of the XDR isolates at up to 18 hours of co-cultivation (Fig. 5). The jumbo phage PhiKZ significantly inhibits the growth of the three XDR *P. aeruginosa* isolates at all multiplicity of infection (MOI), including the lowest MOI tested of 0.1 (Fig. 6, panels A, E, and I). Jumbo phage PhiPizzaParty significantly inhibits PS748 and PS749, but does not show significant growth inhibition of PS747. The non-jumbo phage Good Vibes does not show a significant inhibition in any of the isolates regardless of the MOI used (Fig. 6, panels C, G, and K). The three XDR *P. aeruginosa* strains were significantly inhibited by a phage cocktail containing equivalent amounts of PhiKZ, PhiPizzaParty, and GoodVibes (Fig. 6, panels D, H, and L).

DISCUSSION

We identified three jumbo phages with significant activity against three XDR *P. aeruginosa* isolates associated with a recently described multi-state outbreak among users of ophthalmic eye drops on solid and in liquid medium. We also identified a non-jumbo phage with significant activity on a solid medium. While we do not have specific information on some of these phages to describe their receptors and interactions with their host *P. aeruginosa* strains, the jumbo phages are similar to previously used phages such as OMKO1 (25), which already have been used rather extensively in phage therapy applications. The use of jumbo phages that have nucleus-like structures may have certain advantages compared to more conventional bacteriophage therapies, as the nuclear shell excludes many DNA-targeting anti-phage systems (20, 21, 26). The phages we identified in this study (ANB1, PhiPizzaParty, and Teru) were all identified from wastewater on the UCSD campus, strongly suggesting that these phages are already circulating through the population.

It is important to note that carbapenems are often the last line of therapy for the treatment of many pathogens but this is not necessarily the case for *P. aeruginosa*. This is because the organism can have multiple different mechanisms by which it can resist carbapenems (27), which may persist after the organism is cured of the VIM betalactamase. In many cases of *P. aeruginosa*, aminoglycoside antibiotics such as amikacin represent the last line of therapy, but in this case, each of the isolates was already resistant to aminoglycosides. These isolates present medical conundrums for therapy, as they are resistant to most commonly used antibiotics, and by the time most laboratories would be able to test for susceptibility to secondary antibiotics such as colistin and cefiderocol, the infection could become much more difficult to eradicate. The knowledge




FIG 5 Inhibition of bacteria growth by phages in liquid media. Experiments were performed at an MOI of 0.1 (A–C), 1 (D–F), 10 (G–I), and maximum phage titer achievable (J–L). Three bacterial strains were used: *P. aeruginosa* PS747 (A, D, G, H), *P. aeruginosa* PS748 (B, E, H, K), and *P. aeruginosa* PS749 (C, F, I, L).

that PhiKZ (a widely available phage) has significant activity against these isolates could make it a candidate for use in phage therapy applications against these XDR *P. aeruginosa* isolates.

One of the primary concerns with the use of phages to treat bacterial infections is the potential that phages may integrate into the host genomes and cause long-term phage infections rather than immediate lysis. We did not identify any genes in either PhiPizza-Party, ANB1, or Teru, which would suggest they have the potential for lysogenic infections. PhiKZ-like phages also degrade the host chromosome early in infection further decreasing the likelihood of lysogenic infection (28, 29). Given the immense concern for the continued spread of these XDR isolates with the use of contaminated eye drops, and the relatively few antibiotics that may be effective, the development/purification of phages such as those identified here could offer critical treatment alternatives to eliminate the ongoing risk from these XDR *P. aeruginosa* strains.

MATERIALS AND METHODS

Bacterial strains, bacteriophages, and culture conditions

P. aeruginosa strains used in the study (Table S2) were previously isolated from patients with *Pseudomonas* infection at the UCSD Centre for Advanced Laboratory Medicine. The




FIG 6 Area under the curve (AUC) measurements over different multiplicity of infection (MOI). t-test with multiple comparison corrections. *P < 0.05, **P < 0.01, and ***P < 0.001.

antibiotic sensitivity testing was performed on the isolates using MicroScan NM46 and DNM2 panels. The phages used in this study were previously isolated from various environmental sources (Table S3). Luria-Bertani (LB) media was used to grow the *P. aeruginosa* strains and phages at 37°C.

Jumbo phage isolation

Wastewater was collected from the UCSD campus through the wastewater monitoring program (30, 31), and from several locations in southern California (Table S3). Jumbo phage isolation and purification were carried out as previously described (32). Wastewater was centrifuged at $3,000 \times g$ for 10 min. The supernatant was collected and centrifuged at $4,696 \times g$ for 55 min. The supernatant was removed, and the pellet was resuspended in 10 mL of SM buffer; this process was performed twice. The sample was treated with an equal volume of chloroform to remove residual bacteria. Plaques were purified three times in 0.3% LB agar plates. Phages were produced by plate lysis in 0.1% LB agar.

Whole genome sequencing

Total genomic DNA from the bacteriophages and bacteria was extracted using the QIAamp UltraSens Virus kit (Qiagen catalog number 53706) or the DNeasy Blood & Tissue Kit (Qiagen catalog number 69504) respectively. Genome sequencing of phages and bacterial isolates was carried out using a paired-end approach (2 × 150 bp) on iSeq100 or Miseq platforms (Illumina), respectively. Phage sequences were assembled using *de novo* assembly algorithm of CLC Genomics Workbench (CLC Genomics, Qiagen, version 9.5.3). Rapid Annotation using Subsystem Technology pipeline (v2.0) was used to annotate the phage sequences (33). For Nanopore sequencing, bacterial DNA was extracted using the ZYMO DNA Microprep kit. Libraries were constructed using the rapid sequencing kit and sequenced on the MinION platform. Illumina and Nanopore reads were used for a hybrid assembly using SPAdes (34). Bacterial genomes were annotated using the BV-BCR (bacterial and viral bioinformatics resource center) resources (33). Antibiotic-resistance genes were obtained from BV-BCR annotations against the CARD database (35). Defense mechanisms were characterized using DefenseFinder (36).

Host range evaluation and efficiency of plating

P. aeruginosa isolates listed in Table S2 were incubated overnight at 37°C. The next day, 100 µL of bacterial culture with an OD₆₀₀ of 0.2 was mixed with 3 mL of melted LB soft agar (when soft agar temperature reaches ~45°C). This mixture was then overlaid on an LB Agar plate (1.5% Agar). A 5 µL sample of serially diluted phages and a 5 µL LB control were spotted onto the bacterial overlay, left for 30 min to dry, and then the plates were incubated overnight at 37°C. The next day, the number of plaques was counted. The EOP assays were carried out as previously described (34) using the reference strain *Pseudomonas aeruginosa* PA01 as the indicator strain. Phage titers for EOP calculations were obtained in triplicate and the average of phage titer was used for EOP calculations.

Phage characterization using transmission electron microscopy

A carbon-coated grid (PELCO SynapTek Grids, product# 01754-F) was placed on a drop of 10 μ L of freshly made phage stock (~10¹⁰ PFU/mL), and the grids were negatively stained with 2% uranyl acetate (pH 4.0) for 45 s. Imaging was performed using Joel 1400 plus at the University of California, San Diego—Cellular and Molecular Medicine Electron Microscopy Core (RRID: SCR_022039).

Fluorescence microscopy of phage-infected Pseudomonas aeruginosa

PA01 was grown in LB to an OD₆₀₀ of 0.5 and incubated with high titer phage lysate at a ratio of 1:100 lysate-to-culture at 30°C with agitation for 30 min. FM4-64 dye was added to the cells at a final concentration of 6.5 µg/mL and then the culture was spotted onto a 1% agarose 25% LB pads containing 0.6 µg/mL DAPI and visualized on an Applied Precision DV Elite optical sectioning microscope with a Photometrics CoolSNAP-HQ2 camera (Applied Precision/GE Healthcare). Microscopic images were deconvolved using SoftWoRx v5.5.1. Image analysis and processing were performed in Fiji.

Liquid phage/bacteria assays

The phage and bacterial co-cultivation assays were performed at an MOI of 0.1, 1, 10, and maximum. The bacterial cells from the exponential phase were diluted to an OD_{600}

of 0.1 in fresh LB broth. Each well within 96-well plate was inoculated with 30 μ L of phage + 60 μ L of bacteria (OD₆₀₀ 0.1) and the remaining volume of MacConkey media was added to a total volume of 200 μ L. For the phage cocktail, 10 μ L of each phage dilution was added. The OD₆₀₀ was measured every 15 min at 37°C for 18 hours. The OD₆₀₀ measurements were used to calculate the area under the curve (AUC) using the R package GrowthCurver (37) using the area under the logistic curve function (SummarizeGrowth, auc_l). AUC values were compared using a *t*-test, *P*-values were corrected for multiple comparisons, and calculations were made using the R package ggstatsplots (38).

ACKNOWLEDGMENTS

We thank the UCSD Clinical Microbiology Laboratory for their participation in this work. We also thank the CDC for their generous sharing of the PSA isolates. We thank Dr. Elizabeth Villa and the EPI consortium for fruitful discussions.

This work was supported by the Howard Hughes Medical Institute Emerging Pathogens Initiative grant (#30207345).

D.T.P. and R.T.S. conceived and designed the project. A.G.C.G., P.G., A.N.B., A.G., J.L., J.O., M.C., P.K., and M.P. performed the experiments. A.G.C.G., P.G., A.N.B., A.G., D.T.P., and R.T.S. analyzed the data. A.G.C.G., P.G., J.P., D.T.P., and R.T.S. wrote and edited the manuscript. S.K. and R.K. provided materials for the study. All authors have reviewed the manuscript.

AUTHOR AFFILIATIONS

¹Department of Pathology, University of California San Diego, La Jolla, California, USA ²Department of Biology, University of California San Diego, La Jolla, California, USA ³Department of Environmental Science and Engineering, Division of Engineering and Applied Science, California Institute of Technology, Pasadena, California, USA

⁴Department of Pediatrics, University of California San Diego, La Jolla, California, USA

⁵Center for Microbiome Innovation, University of California San Diego, La Jolla, California, USA

⁶Department of Bioengineering, University of California San Diego, La Jolla, California, USA

⁷Department of Computer Sciences & Engineering, University of California San Diego, La Jolla, California, USA

⁸Howard Hughes Medical Institute, University of California San Diego, La Jolla, California, USA

⁹Department of Medicine, University of California San Diego, La Jolla, California, USA

AUTHOR ORCIDs

Ana Georgina Cobián Güemes b http://orcid.org/0000-0002-0755-5864 Rob Knight b http://orcid.org/0000-0002-0975-9019 David T. Pride b http://orcid.org/0000-0001-8161-6015

FUNDING

Funder	Grant(s)	Author(s)
Howard Hughes Medical Institute (HHMI)	30207345	Ana Georgina Cobián Güemes

AUTHOR CONTRIBUTIONS

Ana Georgina Cobián Güemes, Conceptualization, Formal analysis, Methodology, Software, Visualization, Writing – original draft, Writing – review and editing | Pooja Ghatbale, Investigation, Methodology, Visualization | Alisha N. Blanc, Methodology | Chase J. Morgan, Methodology | Andrew Garcia, Investigation, Methodology | Jesse Leonard, Methodology | Lina Huang, Investigation, Methodology | Grace Kovalick, Investigation, Methodology | Marissa Proost, Investigation, Methodology | Megan Chiu, Investigation, Methodology | Peiting Kuo, Investigation, Methodology | Joseph Oh, Investigation | Smruthi Karthikeyan, Resources | Rob Knight, Methodology, Resources, Writing – review and editing | Joe Pogliano, Writing – review and editing | Robert T. Schooley, Conceptualization, Writing – original draft, Writing – review and editing | David T. Pride, Conceptualization, Supervision, Writing – original draft, Writing – review and editing

DATA AVAILABILITY

All sequences included in this study have been deposited in the NCBI Sequence Read Archive under BioProject PRJNA971669.

ADDITIONAL FILES

The following material is available online.

Supplemental Material

Supplemental Material (AAC00654-23-s0001.docx). Table S1 to S5 and Fig. S1 and S2.

REFERENCES

- Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, et al. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
- Ma Y, Wang C, Li Y, Li J, Wan Q, Chen J, Tay FR, Niu L. 2020. Considerations and Caveats in combating ESKAPE pathogens against nosocomial infections. Advanced Science 7. https://doi.org/10.1002/advs.201901872
- Sundermann AJ, Rangachar Srinivasa V, Mills EG, Griffith MP, Waggle KD, Ayres AM, Pless L, Snyder GM, Harrison LH, Van Tyne D. 2023. Two artificial tears outbreak-associated cases of XDR *Pseudomonas aeruginosa* detected through whole genome sequencing-based surveillance. J Infect Dis, September:jiad318. https://doi.org/10.1093/ infdis/jiad318
- Shoji MK, Gutkind NE, Meyer BI, Yusuf R, Sengillo JD, Amescua G, Miller D. 2023. Multidrug-resistant *Pseudomonas aeruginosa* Keratitis associated with artificial tear use. JAMA Ophthalmol 141:499–500. https: //doi.org/10.1001/jamaophthalmol.2023.1109
- Morelli MK, Kloosterboer A, Omar AF. 2023. Pseudomonas aeruginosa corneal ulcer associated with artificial tears eye drops. JAMA Ophthalmol 141:496. https://doi.org/10.1001/jamaophthalmol.2023.1105
- 6. CDC.Outbreak of Extensively Drug-resistant *Pseudomonas aeruginosa* Associated with Artificial TearsCDC
- Partridge SR, Kwong SM, Firth N, Jensen SO. 2018. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev 31:e00088–17. https://doi.org/10.1128/CMR.00088-17
- Meletis G, Vavatsi N, Exindari M, Protonotariou E, Sianou E, Haitoglou C, Sofianou D, Pournaras S, Diza E. 2014. Accumulation of carbapenem resistance mechanisms in VIM-2-producing *Pseudomonas aeruginosa* under selective pressure. Eur J Clin Microbiol Infect Dis 33:253–258. https://doi.org/10.1007/s10096-013-1952-3
- Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. 2023. Phage therapy: from biological mechanisms to future directions. Cell 186:17–31. https:// doi.org/10.1016/j.cell.2022.11.017
- Burmeister AR, Fortier A, Roush C, Lessing AJ, Bender RG, Barahman R, Grant R, Chan BK, Turner PE. 2020. Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci U S A 117:11207–11216. https://doi.org/10.1073/pnas.1919888117
- Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, Kadioglu A. 2017. Phage therapy is highly effective against chronic lung infections with *Pseudomonas aeruginosa* Thorax 72:666–667. https://doi. org/10.1136/thoraxjnl-2016-209265
- Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H. 2019. Engineered bacteriophages for treatment of a patient

with a disseminated drug-resistant mycobacterium abscessus. Nat Med 25:730–733. https://doi.org/10.1038/s41591-019-0437-z

- Sabnis A, Hagart KL, Klöckner A, Becce M, Evans LE, Furniss RCD, Mavridou DA, Murphy R, Stevens MM, Davies JC, Larrouy-Maumus GJ, Clarke TB, Edwards AM. 2021. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. Elife 10:e65836. https: //doi.org/10.7554/eLife.65836
- Krylov V, Bourkaltseva M, Pleteneva E, Shaburova O, Krylov S, Karaulov A, Zhavoronok S, Svitich O, Zverev V. 2021. Phage phiKZ—the first of giants. Viruses 13:149. https://doi.org/10.3390/v13020149
- Monson R, Foulds I, Foweraker J, Welch M, Salmond GPC. 2011. "The *Pseudomonas aeruginosa* generalized transducing phage ΦPA3 is a new member of the ΦKZ-like group of 'jumbo' phages, and infects model laboratory strains and clinical isolates from cystic fibrosis patients". Microbiology (Reading) 157:859–867. https://doi.org/10.1099/mic.0. 044701-0
- Latz S, Krüttgen A, Häfner H, Buhl EM, Ritter K, Horz H-P. 2017. Differential effect of newly isolated phages belonging to PB1-like, phiKZlike and LUZ24-like viruses against multi-drug resistant *Pseudomonas aeruginosa* under varying growth conditions. Viruses 9:315. https://doi. org/10.3390/v9110315
- Chaikeeratisak Vorrapon, Nguyen K, Khanna K, Brilot AF, Erb ML, Coker JKC, Vavilina A, Newton GL, Buschauer R, Pogliano K, Villa E, Agard DA, Pogliano J. 2017. Assembly of a nucleus-like structure during viral replication in bacteria. Science 355:194–197. https://doi.org/10.1126/ science.aal2130
- Chaikeeratisak V, Nguyen K, Egan ME, Erb ML, Vavilina A, Pogliano J. 2017. The phage nucleus and tubulin spindle are conserved among large *Pseudomonas* phages. Cell Rep 20:1563–1571. https://doi.org/10. 1016/j.celrep.2017.07.064
- Knipe DM, Prichard A, Sharma S, Pogliano J. 2022. Replication compartments of eukaryotic and bacterial DNA viruses: common themes between different domains of host cells. Annu Rev Virol 9:307–327. https://doi.org/10.1146/annurev-virology-012822-125828
- Mendoza SD, Nieweglowska ES, Govindarajan S, Leon LM, Berry JD, Tiwari A, Chaikeeratisak V, Pogliano J, Agard DA, Bondy-Denomy J. 2020. A bacteriophage nucleus-like compartment shields DNA from CRISPR nucleases. Nature 577:244–248. https://doi.org/10.1038/s41586-019-1786-y
- Malone LM, Warring SL, Jackson SA, Warnecke C, Gardner PP, Gumy LF, Fineran PC. 2020. A jumbo phage that forms a nucleus-like structure evades CRISPR–Cas DNA targeting but is vulnerable to type III RNAbased immunity. Nat Microbiol 5:48–55. https://doi.org/10.1038/s41564-019-0612-5

- 22. Prichard A, Lee J, Laughlin TG, Lee A, Thomas KP, Sy AE, Spencer T, Asavavimol A, Cafferata A, Cameron M, Chiu N, Davydov D, Desai I, Diaz G, Guereca M, Hearst K, Huang L, Jacobs E, Johnson A, Kahn S, Koch R, Martinez A, Norquist M, Pau T, Prasad G, Saam K, Sandhu M, Sarabia AJ, Schumaker S, Sonin A, Uyeno A, Zhao A, Corbett KD, Pogliano K, Meyer J, Grose JH, Villa E, Dutton R, Pogliano J. 2023. Identifying the core genome of the nucleus-forming bacteriophage family and characterization of *Erwinia* phage RAY. Cell Rep 42:112432. https://doi.org/10.1016/j.celrep. 2023.112432
- Laughlin TG, Deep A, Prichard AM, Seitz C, Gu Y, Enustun E, Suslov S, Khanna K, Birkholz EA, Armbruster E, McCammon JA, Amaro RE, Pogliano J, Corbett KD, Villa E. 2022. Architecture and self-assembly of the jumbo bacteriophage nuclear shell. Nature 608:429–435. https://doi. org/10.1038/s41586-022-05013-4
- Ackermann HW. 2009. Phage classification and characterization. Methods Mol Biol 501:127–140. https://doi.org/10.1007/978-1-60327-164-6_13
- Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. 2016. Phage selection restores antibiotic sensitivity in MDR *Pseudomonas* aeruginosa. Sci Rep 6:26717. https://doi.org/10.1038/srep26717
- Nguyen KT, Sugie J, Khanna K, Egan ME, Birkholz EA, Lee J, Beierschmitt C, Villa E, Pogliano J. 2021. Selective transport of fluorescent proteins into the phage nucleus. Edited by B. Kumar. PLOS ONE 16:e0251429. https://doi.org/10.1371/journal.pone.0251429
- Pai H, Kim JW, Kim J, Lee JH, Choe KW, Gotoh N. 2001. Carbapenem resistance mechanisms in *Pseudomonas aeruginosa* clinical isolates. Antimicrob Agents Chemother 45:480–484. https://doi.org/10.1128/ AAC.45.2.480-484.2001
- Kraemer JA, Erb ML, Waddling CA, Montabana EA, Zehr EA, Wang H, Nguyen K, Pham DSL, Agard DA, Pogliano J. 2012. A phage tubulin assembles dynamic filaments by an atypical mechanism to center viral DNA within the host cell. Cell 149:1488–1499. https://doi.org/10.1016/j. cell.2012.04.034
- Erb ML, Kraemer JA, Coker JKC, Chaikeeratisak V, Nonejuie P, Agard DA, Pogliano J. 2014. A bacteriophage tubulin harnesses dynamic instability to center DNA in infected cells. Elife 3:e03197. https://doi.org/10.7554/ eLife.03197
- Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, Farmer S, Tubb HM, Valles T, Tribelhorn CE, et al. 2022. Wastewater

sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature 609:101–108. https://doi.org/10.1038/s41586-022-05049-6

- Fielding-Miller R, Karthikeyan S, Gaines T, Garfein RS, Salido RA, Cantu VJ, Kohn L, Martin NK, Wynn A, Wijaya C, et al, SEARCH. 2023. Safer at school early alert: an observational study of wastewater and surface monitoring to detect COVID-19 in elementary schools. Lancet Reg Health Am 19:100449. https://doi.org/10.1016/j.lana.2023.100449
- Saad AM, Soliman AM, Kawasaki T, Fujie M, Nariya H, Shimamoto T, Yamada T. 2019. Systemic method to isolate large bacteriophages for use in biocontrol of a wide-range of pathogenic bacteria. J Biosci Bioeng 127:73–78. https://doi.org/10.1016/j.jbiosc.2018.07.001
- Wattam AR, Davis JJ, Assaf R, Boisvert S, Brettin T, Bun C, Conrad N, Dietrich EM, Disz T, Gabbard JL, et al. 2017. Improvements to PATRIC, the all-bacterial Bioinformatics database and analysis resource center. Nucleic Acids Res 45:D535–D542. https://doi.org/10.1093/nar/gkw1017
- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb. 2012.0021
- 35. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, Lago BA, Dave BM, Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE, Frye JG, Elsayegh T, Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FSL, Wright GD, McArthur AG. 2017. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res 45:D566–D573. https://doi.org/10.1093/nar/ gkw1004
- Abby SS, Néron B, Ménager H, Touchon M, Rocha EPC, ed. 2014. MacSyFinder: a program to mine genomes for molecular systems with an application to CRISPR-Cas systems. PLoS ONE 9:e110726. https://doi. org/10.1371/journal.pone.0110726
- Sprouffske K, Wagner A. 2016. Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves. BMC Bioinformatics 17:172. https://doi.org/10.1186/s12859-016-1016-7
- Patil I. 2021. "Visualizations with statistical details: the "ggstatsplot" approach". JOSS 6:3167. https://doi.org/10.21105/joss.03167